These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7804724)

  • 41. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
    Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
    Li D; Zhang X; Song Y
    Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 47. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM; Beutel LD; Nayak SK; Dillman RO
    J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-derived activated cells: culture conditions and characterization.
    Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
    Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
    [No Abstract]   [Full Text] [Related]  

  • 49. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.
    Whiteside TL; Heo DS; Takagi S; Herberman RB
    Immunol Ser; 1989; 48():139-57. PubMed ID: 2488318
    [No Abstract]   [Full Text] [Related]  

  • 51. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
    Mallmann P; Krebs D
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparison of antitumor activity of tumor draining lymph node lymphocytes and peripheral blood lymphocytes in human oral cancer].
    Guo W; Qiu WL; He RG
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1994 Nov; 29(6):336-8, 384. PubMed ID: 7743875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC).
    Oldham RK; Lewko WM; Good RW; Sharp E
    In Vivo; 1994; 8(5):653-63. PubMed ID: 7537108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential regulation by interleukin-4 and interferon-gamma of an autologous melanoma-specific cytotoxic T-cell clone and the tumor-infiltrating lymphocytes from which it was established.
    Yamada T; Holmes EC; Golub SH
    Cancer Commun; 1990; 2(3):113-21. PubMed ID: 2114166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Study on adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) for renal cell carcinoma--amplification of IL-2-elicited TIL proliferation by OKT3-monoclonal antibody].
    Hayakawa M; Sisido S; Higa I; Koyama Y; Hatano T; Osawa A
    Nihon Hinyokika Gakkai Zasshi; 1990 Jan; 81(1):103-9. PubMed ID: 2304307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 57. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
    Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
    Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
    Strome SE; Krauss JC; Chang AE; Shu S
    J Hematother; 1993; 2(1):63-73. PubMed ID: 7921967
    [No Abstract]   [Full Text] [Related]  

  • 59. Implementation of an effective program for quality assurance and quality control in living cell therapy: a 2-year experience with autolymphocyte therapy.
    du Moulin GC; Liu V; Osband ME
    Transplant Proc; 1992 Dec; 24(6):2803-8. PubMed ID: 1465947
    [No Abstract]   [Full Text] [Related]  

  • 60. [Interleukin-2 based immunotherapy of cancer].
    Geertsen PF; Hermann GG; Claësson MH; Steven K; Zeuthen J; von der Maase H
    Ugeskr Laeger; 1990 Nov; 152(47):3513-7. PubMed ID: 2256204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.